New Zealand Gene Therapy

Our mission is to improve the lives of those with severe vision loss using retinal gene therapy.

Our work expands upon the pioneering work of our lead scientist, Dr Jean Bennett, and her first FDA- approved gene therapy drug in the USA and the first gene therapy drug approved worldwide, Luxturna that is now used to treat a congenital blindness caused by mutations in the RPE65 gene in children and adults.

Please send us an email for more information:
info@nzgenetherapy.com